T-03
PT-141 study-dose explorer
Every dose any bremelanotide (or precursor Melanotan-II) trial actually tested, sortable by population, route, dose and year, with outcome, grade and integrity flags. Exists so any quoted 'PT-141 dose' can be checked against what was actually studied.
Every dose you see quoted for PT-141 traces to one of a small number of studies, and the studies disagree with the marketing more than with each other: the approved regimen is a fixed 1.75 mg autoinjector for premenopausal women; the male data are single-dose proof-of-concept studies from 2004 to 2008, two of them now integrity-flagged; and plasma exposure plateaus at 7.5 mg, above which more drug mostly means more nausea window. This table puts every studied dose in one place so a quoted number can be checked against what was actually tested.
Published records (13 of 13)
| Study context | Species | Dose as published | Route |
|---|---|---|---|
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | human | not stated | not stated |
| not stated | rat | not stated | not stated |
Every row restates a published record; sources resolve on the sourced monograph. Species is part of the data: this table never scales an animal dose into a human figure.
Worked example
How to read a claim against this table: a vendor quoting 'PT-141 2 mg for men' is quoting no study at all. The male subcutaneous data are 0.3 to 10 mg single doses (significant above 1 mg in healthy men; 4 to 6 mg in sildenafil non-responders), the male intranasal data are 4 to 20 mg (significant above 7 mg), and the only approved dose in anyone is 1.75 mg SC in premenopausal women with HSDD. No male regimen of any kind was ever approved; FDA's review says those programs did not lead to approved products.
Step by step
- Find the population that matches the claim you are checking: premenopausal women with HSDD (approved), men with ED (former program), obese women (phase 1 mechanism), or rats.
- Read the dose, route and duration columns together: single-dose lab studies say nothing about monthly use.
- Check the outcome column for what was actually measured, and whether the row carries an integrity flag.
- Compare against the label limits in T-01: any regimen beyond 1 dose/24 h or 8/month is outside every human study's protocol except the short daily-dosing safety studies that produced 38% skin darkening.
Tools: educational calculators and references only.